


### Claims

1. A compound having the general formula I:



wherein

X<sup>1</sup> is, independently at each occurrence, selected from CH and N;

X<sup>2</sup> is, independently at each occurrence, selected from CH and N;

Y<sup>1</sup> is, independently at each occurrence, selected from CH<sub>2</sub>, CH(CH<sub>3</sub>)CH<sub>2</sub>, C(CH<sub>3</sub>)<sub>2</sub>, C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub> and CH<sub>2</sub>CH<sub>2</sub>;

n is, independently at each occurrence, selected from 0 and 1;

R<sup>1</sup> is, at each occurrence, independently selected from the group consisting of C1-C6 alkyl and C1-C3 haloalkyl;


R<sup>2</sup> is, at each occurrence, independently selected from the group consisting of C1-C6 alkyl and C1-C3 haloalkyl, any of which is optionally substituted;

R<sup>3</sup> is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, e. g. Cl or F, C1-C3 alkyl, which is optionally substituted, and NHCH(CH<sub>3</sub>)CH<sub>3</sub>;

R<sup>4</sup> is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, e. g. Cl or F, NHCH(CH<sub>3</sub>)<sub>2</sub>, -CH<sub>2</sub>OH, C1-C3 alkyl, which is optionally substituted, alkoxy, in particular C<sub>1</sub>-C<sub>3</sub> alkoxy, e.g. methoxy, and -CF<sub>3</sub>;

R<sup>5</sup> is, at each occurrence, independently selected from the group consisting of C1-C6 alkyl, C1-C6 alkyl substituted with C1-C6 cycloalkyl, with heterocyclyl or with O-(C1-C6 alkyl); C1-C3 haloalkyl, e.g. CH<sub>2</sub>F, CHF<sub>2</sub>, CF<sub>3</sub>, CH<sub>2</sub>CF<sub>3</sub>, N,N-dimethylethane-amino, N,N-

Z<sup>1</sup> is, at each occurrence, independently selected from the group consisting of hydrogen, hydroxyl, C1-C6 alkyl, C(O)R<sup>7</sup>, C(O)NHR<sup>7</sup>, C(O)OR<sup>7</sup>, CN, C(O)R<sup>8</sup>, C(O)OR<sup>8</sup>, N(R<sup>7</sup>)<sub>2</sub>, OR<sup>8</sup>, OCH<sub>3</sub>, OCH<sub>2</sub>F, OCHF<sub>2</sub>, OCF<sub>3</sub> and any structure of the following group **A**, any structure of which is optionally substituted;



R<sup>9</sup> is, at each occurrence, independently selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 cycloalkyl, C1-C6 alkyl substituted with C1-C6 cycloalkyl; C1-C6 alkenyl, heterocyclyl, C1-C3 haloalkyl, e.g. CH<sub>2</sub>F, CHF<sub>2</sub>, CF<sub>3</sub>, CH<sub>2</sub>CF<sub>3</sub>, C(O)OR<sup>7</sup>, CH<sub>2</sub>C(O)OR<sup>7</sup>, C(O)R<sup>7</sup>, -(CH<sub>2</sub>)<sub>m</sub>NR<sup>7</sup>R<sup>13</sup>, -(CH<sub>2</sub>)<sub>m</sub>OR<sup>7</sup>, OR<sup>8</sup>, alkoxy, in particular C1-C3 alkoxy, e.g. methoxy, haloalkoxy, e.g. OCF<sub>3</sub>, aryloxy, in particular phenoxy, C(CH<sub>3</sub>)<sub>2</sub>OH, C(CH<sub>3</sub>)(OH)CH<sub>2</sub>OH,

N,N-dimethylethane-amino, F, Cl, NO<sub>2</sub>, NH<sub>2</sub>, CN, aryl, in particular benzyl or phenyl, benzyl hydroxyl and pyrrolidinyl, any of which is optionally substituted, m being an integer, independently at each occurrence, selected from 0, 1, 2, and 3;

R<sup>10</sup> is, at each occurrence, independently selected from the group consisting of hydrogen, hydroxyl, halogen, e.g. F, Cl, C1-C6 alkyl, C1-C3 haloalkyl, e.g. CH<sub>2</sub>F, CHF<sub>2</sub>, CF<sub>3</sub>, CH<sub>2</sub>CF<sub>3</sub>, C(O)R<sup>7</sup>, e. g. CH<sub>2</sub>F, CHF<sub>2</sub>, CF<sub>3</sub>, CH<sub>2</sub>NR<sup>7</sup>R<sup>13</sup>, CH<sub>2</sub>OH, C(O)NR<sup>7</sup>R<sup>13</sup>, NO<sub>2</sub>, and CN, any of which is optionally substituted;

R<sup>11</sup> is, at each occurrence, independently selected from the group consisting of hydrogen, hydroxyl, C1-C6 alkyl, C1-C3 haloalkyl, e. g. CH<sub>2</sub>F, CHF<sub>2</sub>, CF<sub>3</sub>, CH<sub>2</sub>CF<sub>3</sub>, C(O)OR<sup>7</sup>, C(CH<sub>3</sub>)<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>NR<sup>7</sup>R<sup>13</sup>, -(CH<sub>2</sub>)<sub>m</sub>NR<sup>7</sup>R<sup>13</sup>, CH<sub>2</sub>OH, alkoxy, in particular C1-C3 alkoxy, e.g. methoxy, haloalkoxy, e.g. OCF<sub>3</sub>, halogen, e.g. F, Cl, CN, NO<sub>2</sub>, NH<sub>2</sub>, NH<sub>2</sub>-(CH<sub>2</sub>)<sub>m</sub> aryl, -(CH<sub>2</sub>)<sub>m</sub> heteroaryl, -NH(C1-C6 alkyl), and OR<sup>8</sup>, any of which is optionally substituted; m being an integer, independently at each occurrence, selected from 0, 1, 2 and 3;

R<sup>12</sup> is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, in particular Cl or F, C1-C6 alkyl, C1-C6 alkyl substituted with C1-C6 cycloalkyl; C1-C6 cycloalkyl, heterocycloalkyl any of which is optionally substituted, -(CH<sub>2</sub>)<sub>m</sub>NR<sup>7</sup>R<sup>13</sup>, m being an integer independently at each occurrence selected from 0, 1, 2 and 3;

R<sup>13</sup> is, at each occurrence, independently selected from the group consisting of hydrogen and C1-C6 alkyl, COMe, CONH<sub>2</sub>, any of which is optionally substituted;

Wherein, if n is 0, X<sup>1</sup> is CH, X<sup>2</sup> is CH, R<sup>1</sup> is methyl, R<sup>2</sup> is methyl, R<sup>3</sup> is F, R<sup>4</sup> is hydrogen, R<sup>5</sup> is ethyl, R<sup>6</sup> is hydrogen, Z<sup>1</sup> is phenyl with substituents R<sup>9</sup>-R<sup>12</sup> as depicted in group A, R<sup>9</sup> is hydrogen, R<sup>10</sup> is hydrogen and R<sup>12</sup> is hydrogen, then R<sup>11</sup> is not F;

Wherein, if n is 0, X<sup>1</sup> is CH, X<sup>2</sup> is CH, R<sup>1</sup> is methyl, R<sup>2</sup> is methyl, R<sup>3</sup> is F, R<sup>4</sup> is hydrogen, R<sup>6</sup> is hydrogen, Z<sup>1</sup> is phenyl with substituents R<sup>9</sup>-R<sup>12</sup> as depicted in group A, R<sup>9</sup> is hydrogen, R<sup>10</sup> is hydrogen, R<sup>11</sup> is F and R<sup>12</sup> is hydrogen, then R<sup>5</sup> is not methyl, methylcyclopropyl, N,N-dimethylethane-amino, N,N-dimethylpropan-

1-amino or iso-propyl;

Wherein, if n is 0,  $X^1$  is CH,  $X^2$  is CH,  $R^1$  is methyl,  $R^2$  is methyl,  $R^3$  is F,  $R^4$  is hydrogen,  $R^5$  is ethyl,  $R^6$  is hydrogen,  $Z^1$  is phenyl with substituents  $R^9$ - $R^{12}$  as depicted in group A,  $R^{10}$  is hydrogen,  $R^{11}$  is F and  $R^{12}$  is hydrogen, then  $R^9$  is not methyl or Cl;

Wherein, if n is 0,  $X^1$  is CH,  $X^2$  is CH,  $R^1$  is methyl,  $R^2$  is methyl,  $R^3$  is hydrogen,  $R^4$  is hydrogen,  $R^5$  is ethyl,  $R^6$  is hydrogen,  $Z^1$  is phenyl with substituents  $R^9$ - $R^{12}$  as depicted in group A,  $R^9$  is hydrogen,  $R^{10}$  is hydrogen and  $R^{12}$  is hydrogen, then  $R^{11}$  is not F;

Wherein, if n is 0,  $X^1$  is CH,  $X^2$  is CH,  $R^1$  is methyl,  $R^2$  is methyl,  $R^3$  is hydrogen,  $R^4$  is hydrogen,  $R^6$  is hydrogen,  $Z^1$  is phenyl with substituents  $R^9$ - $R^{12}$  as depicted in group A,  $R^9$  is hydrogen,  $R^{10}$  is hydrogen,  $R^{11}$  is F and  $R^{12}$  is hydrogen, then  $R^5$  is not iso-propyl or methylcyclopropyl;

Wherein, if n is 0,  $X^1$  is CH,  $X^2$  is CH,  $R^1$  is methyl,  $R^2$  is methyl,  $R^3$  is hydrogen,  $R^4$  is hydrogen,  $R^5$  is ethyl,  $R^6$  is hydrogen,  $Z^1$  is phenyl with substituents  $R^9$ - $R^{12}$  as depicted in group A,  $R^9$  is methyl,  $R^{10}$  is hydrogen and  $R^{12}$  is hydrogen, then  $R^{11}$  is not F,

Wherein, if n is 0,  $X^1$  is CH,  $X^2$  is CH,  $R^1$  is methyl,  $R^2$  is methyl,  $R^3$  is methyl,  $R^4$  is hydrogen,  $R^5$  is ethyl,  $R^6$  is hydrogen,  $Z^1$  is phenyl with substituents  $R^9$ - $R^{12}$  as depicted in group A,  $R^9$  is hydrogen,  $R^{10}$  is hydrogen and  $R^{12}$  is hydrogen, then  $R^{11}$  is not F;

Wherein, if n is 0,  $X^1$  is CH,  $X^2$  is CH,  $R^1$  is methyl,  $R^2$  is methyl,  $R^3$  is methyl,  $R^4$  is hydrogen,  $R^6$  is hydrogen,  $Z^1$  is phenyl with substituents  $R^9$ - $R^{12}$  as depicted in group A,  $R^9$  is hydrogen,  $R^{10}$  is hydrogen,  $R^{11}$  is F and  $R^{12}$  is hydrogen, then  $R^5$  is not iso-propyl or methylcyclopropyl;

Wherein, if n is 0,  $X^1$  is CH,  $X^2$  is CH,  $R^1$  is methyl,  $R^2$  is methyl,  $R^3$  is methyl,  $R^4$  is

hydrogen,  $R^5$  is ethyl,  $R^6$  is hydrogen,  $Z^1$  is phenyl with substituents  $R^9$ - $R^{12}$  as depicted in group A,  $R^9$  is methyl,  $R^{10}$  is hydrogen and  $R^{12}$  is hydrogen, then  $R^{11}$  is not F;

Wherein, if n is 0,  $X^1$  is CH,  $X^2$  is CH,  $R^1$  is methyl,  $R^2$  is methyl,  $R^3$  is Cl,  $R^4$  is hydrogen,  $R^5$  is ethyl,  $R^6$  is hydrogen,  $Z^1$  is phenyl with substituents  $R^9$ - $R^{12}$  as depicted in group A,  $R^9$  is hydrogen,  $R^{10}$  is hydrogen and  $R^{12}$  is hydrogen, then  $R^{11}$  is not F;

Wherein, if n is 0,  $X^1$  is CH,  $X^2$  is CH,  $R^1$  is methyl,  $R^2$  is methyl,  $R^3$  is Cl,  $R^4$  is hydrogen,  $R^6$  is hydrogen,  $Z^1$  is phenyl with substituents  $R^9$ - $R^{12}$  as depicted in group A,  $R^9$  is hydrogen,  $R^{10}$  is hydrogen,  $R^{11}$  is F and  $R^{12}$  is hydrogen, then  $R^5$  is not iso-propyl or methylcyclopropyl;

Wherein, if n is 0,  $X^1$  is CH,  $X^2$  is CH,  $R^1$  is methyl,  $R^2$  is methyl,  $R^3$  is Cl,  $R^4$  is hydrogen,  $R^5$  is ethyl,  $R^6$  is hydrogen,  $Z^1$  is phenyl with substituents  $R^9$ - $R^{12}$  as depicted in group A,  $R^9$  is methyl,  $R^{10}$  is hydrogen and  $R^{12}$  is hydrogen, then  $R^{11}$  is not F;

Wherein, if n is 0,  $X^1$  is CH,  $X^2$  is CH,  $R^1$  is methyl,  $R^2$  is methyl,  $R^3$  is F,  $R^4$  is hydrogen,  $R^5$  is ethyl,  $R^6$  is hydrogen,  $Z^1$  is phenyl with substituents  $R^9$ - $R^{12}$  as depicted in group A,  $R^{10}$  is hydrogen,  $R^{11}$  is F and  $R^{12}$  is hydrogen, then  $R^9$  is not N,N-dimethylethane-amino;

Wherein, if n is 0,  $X^1$  is CH,  $X^2$  is N,  $R^1$  is methyl,  $R^2$  is methyl,  $R^3$  is hydrogen,  $R^4$  is hydrogen,  $R^5$  is ethyl,  $R^6$  is hydrogen,  $Z^1$  is phenyl with substituents  $R^9$ - $R^{12}$  as depicted in group A,  $R^9$  is hydrogen,  $R^{10}$  is hydrogen and  $R^{12}$  is hydrogen, then  $R^{11}$  is not F;

Wherein, if n is 0,  $X^1$  is CH,  $X^2$  is N,  $R^1$  is methyl,  $R^2$  is methyl,  $R^3$  is hydrogen,  $R^4$  is hydrogen,  $R^5$  is ethyl,  $R^6$  is hydrogen,  $Z^1$  is phenyl with substituents  $R^9$ - $R^{12}$  as depicted in group A,  $R^{10}$  is hydrogen,  $R^{11}$  is F, and  $R^{12}$  is hydrogen, then  $R^9$  is not methyl, Cl, benzyloxy, or hydroxyl;

Wherein, if  $n$  is 0,  $X^1$  is CH,  $X^2$  is N,  $R^1$  is methyl,  $R^2$  is methyl,  $R^3$  is hydrogen,  $R^4$  is hydrogen,  $R^5$  is ethyl,  $R^6$  is hydrogen,  $Z^1$  is phenyl with substituents  $R^9$ - $R^{12}$  as depicted in group A,  $R^9$  is methyl,  $R^{10}$  is hydrogen and  $R^{12}$  is hydrogen, then  $R^{11}$  is not methoxy;

Wherein, if  $n$  is 0,  $X^1$  is CH,  $X^2$  is CH,  $R^1$  is methyl,  $R^2$  is methyl,  $R^3$  is F,  $R^4$  is hydrogen,  $R^5$  is ethyl,  $R^6$  is hydrogen,  $Z^1$  is phenyl with substituents  $R^9$ - $R^{12}$  as depicted in group A,  $R^9$  is hydrogen,  $R^{11}$  is hydrogen and  $R^{12}$  is hydrogen, then  $R^{10}$  is not  $\text{NO}_2$ ;

Wherein, if  $n$  is 0,  $X^1$  is CH,  $X^2$  is CH,  $R^1$  is methyl,  $R^2$  is methyl,  $R^3$  is F,  $R^4$  is hydrogen,  $R^5$  is ethyl,  $R^6$  is hydrogen,  $Z^1$  is phenyl with substituents  $R^9$ - $R^{12}$  as depicted in group A,  $R^9$  is methyl,  $R^{10}$  is hydrogen and  $R^{12}$  is hydrogen, then  $R^{11}$  is not methoxy;

Wherein, if  $n$  is 0,  $X^1$  is CH,  $X^2$  is N,  $R^1$  is methyl,  $R^2$  is methyl,  $R^3$  is hydrogen,  $R^4$  is hydrogen,  $R^5$  is ethyl,  $R^6$  is hydrogen,  $Z^1$  is phenyl with substituents  $R^9$ - $R^{12}$  as depicted in group A,  $R^9$  is hydrogen,  $R^{11}$  is hydrogen and  $R^{12}$  is hydrogen, then  $R^{10}$  is not  $\text{NO}_2$ ;

Wherein, if  $n$  is 0,  $X^1$  is CH,  $X^2$  is CH,  $R^1$  is methyl,  $R^2$  is methyl,  $R^3$  is hydrogen,  $R^5$  is ethyl,  $R^6$  is hydrogen,  $Z^1$  is phenyl with substituents  $R^9$ - $R^{12}$  as depicted in group A,  $R^9$  is methyl,  $R^{10}$  is hydrogen,  $R^{11}$  is F and  $R^{12}$  is hydrogen, then  $R^4$  is not methoxy or methyl;

Wherein, if  $n$  is 0,  $X^1$  is CH,  $X^2$  is CH,  $R^1$  is methyl,  $R^2$  is methyl,  $R^3$  is F,  $R^4$  is hydrogen,  $R^5$  is ethyl,  $R^6$  is hydrogen,  $Z^1$  is phenyl with substituents  $R^9$ - $R^{12}$  as depicted in group A,  $R^9$  is hydrogen,  $R^{10}$  is methoxy and  $R^{12}$  is hydrogen, then  $R^{11}$  is not F;

Wherein, if  $n$  is 0,  $X^1$  is CH,  $X^2$  is N,  $R^1$  is methyl,  $R^2$  is methyl,  $R^3$  is hydrogen,  $R^4$  is hydrogen,  $R^5$  is ethyl,  $R^6$  is hydrogen,  $Z^1$  is phenyl with substituents  $R^9$ - $R^{12}$  as depicted in

group A,  $R^9$  is hydrogen,  $R^{10}$  is methoxy and  $R^{12}$  is hydrogen, then  $R^{11}$  is not F;

Wherein, if n is 0,  $X^1$  is CH,  $X^2$  is N,  $R^1$  is methyl,  $R^2$  is methyl,  $R^3$  is hydrogen,  $R^4$  is hydrogen,  $R^5$  is ethyl,  $R^6$  is hydrogen,  $Z^1$  is phenyl with substituents  $R^9$ - $R^{12}$  as depicted in group A,  $R^9$  is hydrogen,  $R^{10}$  is hydrogen and  $R^{12}$  is hydrogen, then  $R^{11}$  is not  $NO_2$  or  $NH_2$ ;


Wherein, if n is 0,  $X^1$  is CH,  $X^2$  is CH,  $R^1$  is methyl,  $R^2$  is methyl,  $R^3$  is F,  $R^4$  is hydrogen,  $R^5$  is ethyl,  $R^6$  is hydrogen,  $R^9$  is hydrogen,  $R^{10}$  is hydrogen,  $R^{11}$  is hydrogen and  $R^{12}$  is hydrogen, then  $Z^1$  is not 3-pyridine as depicted in group A;

Wherein, if n is 0,  $X^1$  is CH,  $X^2$  is CH,  $R^1$  is methyl,  $R^2$  is methyl,  $R^3$  is F,  $R^4$  is hydrogen,  $R^5$  is ethyl,  $R^6$  is hydrogen and  $Z^1$  is pyrazole as depicted in group A, then  $R^{13}$  is not methyl;

and pharmaceutically acceptable salts thereof.

2. The compound according to claim 1, wherein one of  $X_1$  and  $X_2$  is N and the other is not, preferably  $X_2$  is N and  $X_1$  is CH.

3. The compound according to any of claims 1 and 2 having the general formula II:



wherein

$Y^2$  is, independently at each occurrence, selected from  $CH_2$  and  $CH_2CH_2$ ;

n is, independently at each occurrence, selected from 0 and 1;


$R^1$  is, at each occurrence, independently selected from the group consisting of C1-C6 alkyl and C1-C3 haloalkyl;

$R^2$  is, at each occurrence, independently selected from the group consisting of C1-C6 alkyl and C1-C3 haloalkyl, any of which is optionally substituted;

$R^5$  is, at each occurrence, independently selected from the group consisting of C1-C6 alkyl, C1-C6 alkyl substituted with C1-C6 cycloalkyl, with heterocyclyl or with O-(C1-C6 alkyl); C1-C3 haloalkyl, e.g.  $\text{CH}_2\text{F}$ ,  $\text{CHF}_2$ ,  $\text{CF}_3$ ,  $\text{CH}_2\text{CF}_3$ , N,N-dimethylethane-amino, N,N-dimethylpropan-1-amino;

$R^6$  is, at each occurrence, independently selected from the group consisting of hydrogen and  $\text{CH}_3$ ;

$Z^2$  is, at each occurrence, independently selected from the group consisting of hydrogen, hydroxyl, C1-C6 alkyl,  $\text{C(O)}R^7$ ,  $\text{C(O)NHR}^7$ , CN,  $\text{C(O)}R^8$ ,  $\text{N(R}^7)_2$ ,  $\text{OR}^8$  and any structure of the following group **B**, any structure of which is optionally substituted;



group **B**

$R^7$  is, at each occurrence, independently selected from the group consisting of hydrogen and C1-C6 alkyl, any of which is optionally substituted;

$R^8$  is, at each occurrence, independently selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C3 haloalkyl, e.g.  $\text{CH}_2\text{F}$ ,  $\text{CHF}_2$ ,  $\text{CF}_3$ ,  $\text{CH}_2\text{CF}_3$ , and phenyl any of which is

optionally substituted;

$R^9$  is, at each occurrence, independently selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 cycloalkyl, C1-C6 alkyl substituted with C1-C6 cycloalkyl; C1-C6 alkenyl, heterocyclyl, C1-C3 haloalkyl, e.g.  $CH_2F$ ,  $CHF_2$ ,  $CF_3$ ,  $CH_2CF_3$ ,  $C(O)OR^7$ ,  $CH_2C(O)OR^7$ ,  $C(O)R^7$ ,  $-(CH_2)_mNR^7R^{13}$ ,  $-(CH_2)_mOR^7$ ,  $OR^8$ , alkoxy, in particular C1-C3 alkoxy, e.g. methoxy, haloalkoxy, e.g.  $OCF_3$ , aryloxy, in particular phenoxy,  $C(CH_3)_2OH$ ,  $C(CH_3)(OH)CH_2OH$ , N,N-dimethylethane-amino, F, Cl,  $NO_2$ ,  $NH_2$ , CN, aryl, in particular benzyl or phenyl, benzyl hydroxyl and pyrrolidinyl, any of which is optionally substituted, m being an integer, independently at each occurrence, selected from 0, 1, 2, and 3;

$R^{10}$  is, at each occurrence, independently selected from the group consisting of hydrogen, hydroxyl, halogen, e.g. F, Cl, C1-C6 alkyl, C1-C3 haloalkyl, e.g.  $CH_2F$ ,  $CHF_2$ ,  $CF_3$ ,  $CH_2CF_3$ ,  $C(O)R^7$ ,  $CH_2NR^7R^{13}$ ,  $CH_2OH$ ,  $C(O)NR^7R^{13}$ ,  $NO_2$  and CN, any of which is optionally substituted;

$R^{11}$  is, at each occurrence, independently selected from the group consisting of hydrogen, hydroxyl, C1-C6 alkyl, C1-C3 haloalkyl, e. g.  $CH_2F$ ,  $CHF_2$ ,  $CF_3$ ,  $CH_2CF_3$ ,  $C(O)OR^7$ ,  $C(CH_3)_2(CH_2)_mNR^7R^{13}$ ,  $-(CH_2)_mNR^7R^{13}$ ,  $CH_2OH$ , alkoxy, in particular C1-C3 alkoxy, e.g. methoxy, haloalkoxy, e.g.  $OCF_3$ , halogen, e.g. F, Cl, CN,  $NO_2$ ,  $NH_2$ ,  $NH_2-(CH_2)_m$  aryl,  $-(CH_2)_m$  heteroaryl,  $-NH(C1-C6 \text{ alkyl})$ , and  $OR^8$ , any of which is optionally substituted; m being an integer, independently at each occurrence, selected from 0, 1, 2 and 3;

$R^{12}$  is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, in particular Cl or F, C1-C6 alkyl, C1-C6 alkyl substituted with C1-C6 cycloalkyl; C1-C6 cycloalkyl, heterocycloalkyl any of which is optionally substituted,  $-(CH_2)_mNR^7R^{13}$ , m being an integer independently at each occurrence selected from 0, 1, 2 and 3;

$R^{13}$  is, at each occurrence, independently selected from the group consisting of hydrogen and C1-C6 alkyl, COMe,  $CONH_2$ , any of which is optionally substituted;

$R^{14}$  and  $R^{15}$  are, at each occurrence, independently selected from the group consisting of

hydrogen, halogen, e.g. F, Cl, and methyl, which is optionally substituted;


Wherein, if n is 0, R<sup>1</sup> is methyl, R<sup>2</sup> is methyl, R<sup>14</sup> is hydrogen, R<sup>15</sup> is hydrogen, R<sup>5</sup> is ethyl, R<sup>6</sup> is hydrogen, Z<sup>2</sup> is phenyl with substituents R<sup>9</sup>-R<sup>12</sup> as depicted in group B, R<sup>9</sup> is hydrogen, R<sup>11</sup> is hydrogen and R<sup>12</sup> is hydrogen,  
then R<sup>10</sup> is not NO<sub>2</sub>;

Wherein, if n is 0, R<sup>1</sup> is methyl, R<sup>2</sup> is methyl, R<sup>14</sup> is hydrogen, R<sup>15</sup> is hydrogen, R<sup>5</sup> is ethyl, R<sup>6</sup> is hydrogen, Z<sup>2</sup> is phenyl with substituents R<sup>9</sup>-R<sup>12</sup> as depicted in group B, R<sup>9</sup> is hydrogen, R<sup>10</sup> is methoxy and R<sup>12</sup> is hydrogen,  
then R<sup>11</sup> is not F;

Wherein, if n is 0, R<sup>1</sup> is methyl, R<sup>2</sup> is methyl, R<sup>14</sup> is hydrogen, R<sup>15</sup> is hydrogen, R<sup>5</sup> is ethyl, R<sup>6</sup> is hydrogen, Z<sup>2</sup> is phenyl with substituents R<sup>9</sup>-R<sup>12</sup> as depicted in group B, R<sup>9</sup> is hydrogen, R<sup>10</sup> is hydrogen and R<sup>12</sup> is hydrogen,  
then R<sup>11</sup> is not NO<sub>2</sub> or NH<sub>2</sub>;

and pharmaceutically acceptable salts thereof.

4. The compound according to claim 1 having the general formula III:



wherein

Y<sup>2</sup> is, independently at each occurrence, selected from CH<sub>2</sub> and CH<sub>2</sub>CH<sub>2</sub>;

n is, independently, at each occurrence, selected from 0 and 1;

R<sup>1</sup> is, at each occurrence, independently selected from the group consisting of C1-C6 alkyl


and C1-C3 haloalkyl;

$R^2$  is, at each occurrence, independently selected from the group consisting of C1-C6 alkyl and C1-C3 haloalkyl, any of which is optionally substituted;

$R^5$  is, at each occurrence, independently selected from the group consisting of C1-C6 alkyl, C1-C6 alkyl substituted with C1-C6 cycloalkyl, with heterocyclyl or with O-(C1-C6 alkyl); C1-C3 haloalkyl, e.g.  $\text{CH}_2\text{F}$ ,  $\text{CHF}_2$ ,  $\text{CF}_3$ ,  $\text{CH}_2\text{CF}_3$ , N,N-dimethylethane-amino, N,N-dimethylpropan-1-amino;

$R^6$  is, at each occurrence, independently selected from the group consisting of hydrogen and  $\text{CH}_3$ ;

$Z^3$  is, at each occurrence, independently selected from any of the structures as depicted in the following group **C**, any structure of which is optionally substituted;



group **C**

$R^7$  is, at each occurrence, independently selected from the group consisting of hydrogen and C1-C6 alkyl, any of which is optionally substituted;

$R^8$  is, at each occurrence, independently selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C3 haloalkyl, e.g.  $\text{CH}_2\text{F}$ ,  $\text{CHF}_2$ ,  $\text{CF}_3$ ,  $\text{CH}_2\text{CF}_3$ , and phenyl any of which is optionally substituted;

$R^9$  is, at each occurrence, independently selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 cycloalkyl, C1-C6 alkyl substituted with C1-C6 cycloalkyl; C1-C6 alkenyl, heterocyclyl, C1-C3 haloalkyl, e.g.  $\text{CH}_2\text{F}$ ,  $\text{CHF}_2$ ,  $\text{CF}_3$ ,  $\text{CH}_2\text{CF}_3$ ,  $\text{C}(\text{O})\text{OR}^7$ ,  $\text{CH}_2\text{C}(\text{O})\text{OR}^7$ ,

$C(O)R^7$ ,  $-(CH_2)_mNR^7R^{13}$ ,  $-(CH_2)_mOR^7$ ,  $OR^8$ , alkoxy, in particular C1-C3 alkoxy, e.g. methoxy, haloalkoxy, e.g.  $OCF_3$ , aryloxy, in particular phenoxy,  $C(CH_3)_2OH$ ,  $C(CH_3)(OH)CH_2OH$ , N,N-dimethylethane-amino, F, Cl,  $NO_2$ ,  $NH_2$ , CN, aryl, in particular benzyl or phenyl, benzyl hydroxyl and pyrrolidinyl, any of which is optionally substituted, m being an integer, independently at each occurrence, selected from 0, 1, 2, and 3;

$R^{11}$  is, at each occurrence, independently selected from the group consisting of hydrogen, hydroxyl, C1-C6 alkyl, C1-C3 haloalkyl, e. g.  $CH_2F$ ,  $CHF_2$ ,  $CF_3$ ,  $CH_2CF_3$ ,  $C(O)OR^7$ ,  $C(CH_3)_2(CH_2)_mNR^7R^{13}$ ,  $-(CH_2)_mNR^7R^{13}$ ,  $CH_2OH$ , alkoxy, in particular C1-C3 alkoxy, e.g. methoxy, haloalkoxy, e.g.  $OCF_3$ , halogen, e.g. F, Cl, CN,  $NO_2$ ,  $NH_2$ ,  $NH_2-(CH_2)_m$  aryl,  $-(CH_2)_m$  heteroaryl,  $-NH(C_1-C_6 \text{ alkyl})$ , and  $OR^8$ , any of which is optionally substituted; m being an integer, independently at each occurrence, selected from 0, 1, 2 and 3;

$R^{12}$  is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, in particular Cl or F, C1-C6 alkyl, C1-C6 alkyl substituted with C1-C6 cycloalkyl; C1-C6 cycloalkyl, heterocycloalkyl any of which is optionally substituted,  $-(CH_2)_mNR^7R^{13}$ , m being an integer independently at each occurrence selected from 0, 1, 2 and 3;

$R^{13}$  is, at each occurrence, independently selected from the group consisting of hydrogen and C1-C6 alkyl, COMe,  $CONH_2$ , any of which is optionally substituted;

$R^{16}$  is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, e.g. F, Cl, and methyl;

$R^{17}$  is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, e.g. F, Cl,  $NHCH(CH_3)_2$ ,  $CF_3$ ,  $-CH_2OH$ , alkoxy, in particular C1-C3 alkoxy, e.g. methoxy, and methyl;

Wherein, if n is 0,  $R^1$  is methyl,  $R^2$  is methyl,  $R^{16}$  is F,  $R^{17}$  is hydrogen,  $R^5$  is ethyl,  $R^6$  is hydrogen,  $Z^3$  is phenyl with substituents  $R^9$  and  $R^{11}$  as depicted in group C, and  $R^9$  is hydrogen, then  $R^{11}$  is not F;

Wherein, if  $n$  is 0,  $R^1$  is methyl,  $R^2$  is methyl,  $R^{16}$  is F,  $R^{17}$  is hydrogen,  $R^6$  is hydrogen,  $Z^3$  is phenyl with substituents  $R^9$  and  $R^{11}$  as depicted in group C,  $R^9$  is hydrogen, and  $R^{11}$  is F, then  $R^5$  is not methyl, methylcyclopropyl, N,N-dimethylethane-amino, N,N-dimethylpropan-1-amino or i-propyl;

Wherein, if  $n$  is 0,  $R^1$  is methyl,  $R^2$  is methyl,  $R^{16}$  is F,  $R^{17}$  is hydrogen,  $R^5$  is ethyl,  $R^6$  is hydrogen,  $Z^3$  is phenyl with substituents  $R^9$  and  $R^{11}$  as depicted in group C, and  $R^{11}$  is F, then  $R^9$  is not methyl or Cl;

Wherein, if  $n$  is 0,  $R^1$  is methyl,  $R^2$  is methyl,  $R^{16}$  is hydrogen,  $R^{17}$  is hydrogen,  $R^5$  is ethyl,  $R^6$  is hydrogen,  $Z^3$  is phenyl with substituents  $R^9$  and  $R^{11}$  as depicted in group C and  $R^9$  is hydrogen, then  $R^{11}$  is not F;

Wherein, if  $n$  is 0,  $R^1$  is methyl,  $R^2$  is methyl,  $R^{16}$  is hydrogen,  $R^{17}$  is hydrogen,  $R^6$  is hydrogen,  $Z^3$  is phenyl with substituents  $R^9$  and  $R^{11}$  as depicted in group C,  $R^9$  is hydrogen and  $R^{11}$  is F, then  $R^5$  is not iso-propyl or methylcyclopropyl;

Wherein, if  $n$  is 0,  $R^1$  is methyl,  $R^2$  is methyl,  $R^{16}$  is hydrogen,  $R^{17}$  is hydrogen,  $R^5$  is ethyl,  $R^6$  is hydrogen,  $Z^3$  is phenyl with substituents  $R^9$  and  $R^{11}$  as depicted in group C, and  $R^9$  is methyl, then  $R^{11}$  is not F;

Wherein, if  $n$  is 0,  $R^1$  is methyl,  $R^2$  is methyl,  $R^{16}$  is methyl,  $R^{17}$  is hydrogen,  $R^5$  is ethyl,  $R^6$  is hydrogen,  $Z^3$  is phenyl with substituents  $R^9$  and  $R^{11}$  as depicted in group C, and  $R^9$  is hydrogen, then  $R^{11}$  is not F;

Wherein, if  $n$  is 0,  $R^1$  is methyl,  $R^2$  is methyl,  $R^{16}$  is methyl,  $R^{17}$  is hydrogen,  $R^6$  is hydrogen,  $Z^3$  is phenyl with substituents  $R^9$  and  $R^{11}$  as depicted in group C,  $R^9$  is hydrogen, and  $R^{11}$  is F, then  $R^5$  is not iso-propyl or methylcyclopropyl;

Wherein, if n is 0, R<sup>1</sup> is methyl, R<sup>2</sup> is methyl, R<sup>16</sup> is methyl, R<sup>17</sup> is hydrogen, R<sup>5</sup> is ethyl, R<sup>6</sup> is hydrogen, Z<sup>3</sup> is phenyl with substituents R<sup>9</sup> and R<sup>11</sup> as depicted in group C, and R<sup>9</sup> is methyl, then R<sup>11</sup> is not F;

Wherein, if n is 0, R<sup>1</sup> is methyl, R<sup>2</sup> is methyl, R<sup>16</sup> is Cl, R<sup>17</sup> is hydrogen, R<sup>5</sup> is ethyl, R<sup>6</sup> is hydrogen, Z<sup>3</sup> is phenyl with substituents R<sup>9</sup> and R<sup>11</sup> as depicted in group C, and R<sup>9</sup> is hydrogen, then R<sup>11</sup> is not F;

Wherein, if n is 0, R<sup>1</sup> is methyl, R<sup>2</sup> is methyl, R<sup>16</sup> is Cl, R<sup>17</sup> is hydrogen, R<sup>6</sup> is hydrogen, Z<sup>3</sup> is phenyl with substituents R<sup>9</sup> and R<sup>11</sup> as depicted in group C, R<sup>9</sup> is hydrogen, and R<sup>11</sup> is F, then R<sup>5</sup> is not iso-propyl or methylcyclopropyl;

Wherein, if n is 0, R<sup>1</sup> is methyl, R<sup>2</sup> is methyl, R<sup>16</sup> is Cl, R<sup>17</sup> is hydrogen, R<sup>5</sup> is ethyl, R<sup>6</sup> is hydrogen, Z<sup>3</sup> is phenyl with substituents R<sup>9</sup> and R<sup>11</sup> as depicted in group C, and R<sup>9</sup> is methyl, then R<sup>11</sup> is not F;

Wherein, if n is 0, R<sup>1</sup> is methyl, R<sup>2</sup> is methyl, R<sup>16</sup> is F, R<sup>17</sup> is hydrogen, R<sup>5</sup> is ethyl, R<sup>6</sup> is hydrogen, Z<sup>3</sup> is phenyl with substituents R<sup>9</sup> and R<sup>11</sup> as depicted in group C, and R<sup>11</sup> is F, then R<sup>9</sup> is not N,N-dimethylethane-amino;


Wherein, if n is 0, R<sup>1</sup> is methyl, R<sup>2</sup> is methyl, R<sup>16</sup> is F, R<sup>17</sup> is hydrogen, R<sup>5</sup> is ethyl, R<sup>6</sup> is hydrogen, Z<sup>3</sup> is phenyl with substituents R<sup>9</sup> and R<sup>11</sup> as depicted in group C, and R<sup>9</sup> is methyl, then R<sup>11</sup> is not methoxy;

Wherein, if n is 0, R<sup>1</sup> is methyl, R<sup>2</sup> is methyl, R<sup>16</sup> is hydrogen, R<sup>5</sup> is ethyl, R<sup>6</sup> is hydrogen, Z<sup>3</sup> is phenyl with substituents R<sup>9</sup> and R<sup>11</sup> as depicted in group C, R<sup>9</sup> is methyl, and R<sup>11</sup> is F, then R<sup>17</sup> is not methoxy or methyl;

Wherein, if n is 0, R<sup>1</sup> is methyl, R<sup>2</sup> is methyl, R<sup>16</sup> is F, R<sup>17</sup> is hydrogen, R<sup>5</sup> is ethyl, R<sup>6</sup> is hydrogen, R<sup>9</sup> is hydrogen, R<sup>11</sup> is hydrogen and R<sup>12</sup> is hydrogen, then Z<sup>3</sup> is not 3-pyridine as depicted in group C;

and pharmaceutically acceptable salts thereof.

5. The compound according to claim 1 having the general formula IV:



wherein

$Y^2$  is, independently at each occurrence, selected from  $CH_2$  and  $CH_2CH_2$ ;

$n$  is, independently at each occurrence, selected from 0 and 1;


$R^1$  is, at each occurrence, independently selected from the group consisting of C1-C6 alkyl and C1-C3 haloalkyl;

$R^2$  is, at each occurrence, independently selected from the group consisting of C1-C6 alkyl and C1-C3 haloalkyl, any of which is optionally substituted;

$R^5$  is, at each occurrence, independently selected from the group consisting of C1-C6 alkyl, C1-C6 alkyl substituted with C1-C6 cycloalkyl, with heterocyclyl or with O-(C1-C6 alkyl); C1-C3 haloalkyl, e.g.  $CH_2F$ ,  $CHF_2$ ,  $CF_3$ ,  $CH_2CF_3$ , N,N-dimethylethane-amino, N,N-dimethylpropan-1-amino;

$R^6$  is, at each occurrence, independently selected from the group consisting of hydrogen and  $CH_3$ ;

$Z^3$  is, at each occurrence, independently selected from any of the structures as depicted in the following group C, any structure of which is optionally substituted;



group C

$R^7$  is, at each occurrence, independently selected from the group consisting of hydrogen and C1-C6 alkyl, any of which is optionally substituted;

$R^8$  is, at each occurrence, independently selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C3 haloalkyl, e.g.  $\text{CH}_2\text{F}$ ,  $\text{CHF}_2$ ,  $\text{CF}_3$ ,  $\text{CH}_2\text{CF}_3$ , and phenyl any of which is optionally substituted;

$R^9$  is, at each occurrence, independently selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 cycloalkyl, C1-C6 alkyl substituted with C1-C6 cycloalkyl; C1-C6 alkenyl, heterocyclyl, C1-C3 haloalkyl, e.g.  $\text{CH}_2\text{F}$ ,  $\text{CHF}_2$ ,  $\text{CF}_3$ ,  $\text{CH}_2\text{CF}_3$ ,  $\text{C}(\text{O})\text{OR}^7$ ,  $\text{CH}_2\text{C}(\text{O})\text{OR}^7$ ,  $\text{C}(\text{O})\text{R}^7$ ,  $-(\text{CH}_2)_m\text{NR}^7\text{R}^{13}$ ,  $-(\text{CH}_2)_m\text{OR}^7$ ,  $\text{OR}^8$ , alkoxy, in particular C1-C3 alkoxy, e.g. methoxy, haloalkoxy, e.g.  $\text{OCF}_3$ , aryloxy, in particular phenoxy,  $\text{C}(\text{CH}_3)_2\text{OH}$ ,  $\text{C}(\text{CH}_3)(\text{OH})\text{CH}_2\text{OH}$ , N,N-dimethylethane-amino, F, Cl,  $\text{NO}_2$ ,  $\text{NH}_2$ , CN, aryl, in particular benzyl or phenyl, benzyl hydroxyl and pyrrolidinyl, any of which is optionally substituted, m being an integer, independently at each occurrence, selected from 0, 1, 2, and 3;

$R^{11}$  is, at each occurrence, independently selected from the group consisting of hydrogen, hydroxyl, C1-C6 alkyl, C1-C3 haloalkyl, e. g.  $\text{CH}_2\text{F}$ ,  $\text{CHF}_2$ ,  $\text{CF}_3$ ,  $\text{CH}_2\text{CF}_3$ ,  $\text{C}(\text{O})\text{OR}^7$ ,  $\text{C}(\text{CH}_3)_2(\text{CH}_2)_m\text{NR}^7\text{R}^{13}$ ,  $-(\text{CH}_2)_m\text{NR}^7\text{R}^{13}$ ,  $\text{CH}_2\text{OH}$ , alkoxy, in particular C1-C3 alkoxy, e.g. methoxy, haloalkoxy, e.g.  $\text{OCF}_3$ , halogen, e.g. F, Cl, CN,  $\text{NO}_2$ ,  $\text{NH}_2$ ,  $\text{NH}_2-(\text{CH}_2)_m$  aryl,  $-(\text{CH}_2)_m$  heteroaryl,  $-\text{NH}(\text{C}_1\text{-C}_6 \text{ alkyl})$ , and  $\text{OR}^8$ , any of which is optionally substituted; m being an integer, independently at each occurrence, selected from 0, 1, 2 and 3;


$R^{12}$  is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, in particular Cl or F, C1-C6 alkyl, C1-C6 alkyl substituted with C1-C6 cycloalkyl; C1-C6 cycloalkyl, heterocycloalkyl any of which is optionally substituted,  $-(\text{CH}_2)_m\text{NR}^7\text{R}^{13}$ , m

being an integer independently at each occurrence selected from 0, 1, 2 and 3;

$R^{13}$  is, at each occurrence, independently selected from the group consisting of hydrogen and C1-C6 alkyl, COMe, CONH<sub>2</sub>, any of which is optionally substituted;

and pharmaceutically acceptable salts thereof.

6. A compound having the general formula V:



wherein

$X^2$  is, independently at each occurrence, selected from CF and N;

$Y^2$  is, independently at each occurrence, selected from CH<sub>2</sub> and CH<sub>2</sub>CH<sub>2</sub>;

$n$  is, independently at each occurrence, selected from 0 and 1;


$R^1$  is, at each occurrence, independently selected from the group consisting of C1-C6 alkyl and C1-C3 haloalkyl;

$R^2$  is, at each occurrence, independently selected from the group consisting of C1-C6 alkyl and C1-C3 haloalkyl, any of which is optionally substituted;

$R^5$  is, at each occurrence, independently selected from the group consisting of C1-C6 alkyl, C1-C6 alkyl substituted with C1-C6 cycloalkyl, with heterocyclyl or with O-(C1-C6 alkyl); C1-C3 haloalkyl, e.g. CH<sub>2</sub>F, CHF<sub>2</sub>, CF<sub>3</sub>, CH<sub>2</sub>CF<sub>3</sub>, N,N-dimethylethane-amino, N,N-dimethylpropan-1-amino;

$Z^4$  is, at each occurrence, independently selected from the group consisting of hydrogen, hydroxyl, C1-C6 alkyl, in particular methyl, ethyl, -N(C1-C6 alkyl)<sub>2</sub>, in particular N(CH<sub>3</sub>)<sub>2</sub>,

alkoxy, in particular C<sub>1</sub>-C<sub>3</sub> alkoxy and haloalkoxy, e. g. OCH<sub>3</sub>, OCH<sub>2</sub>F, OCHF<sub>2</sub>, OCF<sub>3</sub> and any structure of the following group **D**, any structure of which is optionally substituted;



group **D**

R<sup>18</sup> is, at each occurrence, independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, in particular methyl and ethyl;

R<sup>19</sup> is, at each occurrence, independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, in particular methyl, and C<sub>1</sub>-C<sub>3</sub> haloalkyl, e. g. CH<sub>2</sub>F, CHF<sub>2</sub>, CF<sub>3</sub>, CH<sub>2</sub>CF<sub>3</sub>;

R<sup>20</sup> is, at each occurrence, independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, in particular methyl and CH<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>;

R<sup>21</sup> is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, e. g. Cl or F, C<sub>1</sub>-C<sub>6</sub> alkyl, in particular methyl, CH(CH<sub>3</sub>)<sub>2</sub>, C(CH<sub>3</sub>)<sub>3</sub>, C<sub>1</sub>-C<sub>3</sub> haloalkyl, e. g. CH<sub>2</sub>F, CHF<sub>2</sub>, CF<sub>3</sub>, CH<sub>2</sub>CF<sub>3</sub>, NR<sup>18</sup>R<sup>19</sup>, in particular NH<sub>2</sub>, and CN;

and pharmaceutically acceptable salts thereof.

7. The compound according to claim 1-6 for use as a pharmaceutically active agent.

8. The compound of claim 7 for use as an inhibitor of a TAM family receptor tyrosine kinase and/or a Met receptor tyrosine kinase.
9. The compound according to any of claims 7-8 for use in the treatment of a disorder associated with, accompanied by, caused by and/or induced by TAM family receptor tyrosine kinase and/or Met receptor tyrosine kinase, preferably a hyperfunction of said TAM family receptor tyrosine kinase and/or of said Met receptor tyrosine kinase.
10. The compound for use according to claim 9, wherein the TAM family receptor tyrosine kinase induced disorder is selected from hyperproliferative disorders.
11. The compound for use according to claim 10, wherein the hyperproliferative disorders are selected from the group comprising cancer, in particular immune-suppressive cancer and primary tumor metastases.
12. The compound for use according to claim 10, wherein the hyperproliferative disorders are selected refractory cancers.
13. The compound for use according to claim 10, wherein the hyperproliferative disorder is selected from adenocarcinoma, choroidal melanoma, acute leukemia, acoustic neurinoma, ampullary carcinoma, anal carcinoma, astrocytoma, basal cell carcinoma, pancreatic cancer, desmoid tumor, bladder cancer, bronchial carcinoma, breast cancer, Burkitt's lymphoma, corpus cancer, CUP-syndrome, colorectal cancer, small intestine cancer, small intestinal tumors, ovarian cancer, endometrial carcinoma, ependymoma, epithelial cancer types, Ewing's tumors, gastrointestinal tumors, gastric cancer, gallbladder cancer, gall bladder carcinomas, uterine cancer, cervical cancer, cervix, glioblastomas, gynecologic tumors, ear tumors, nose tumors and throat tumors, hematologic neoplasias, hairy cell leukemia, urethral cancer, skin cancer, skin testis cancer, brain tumors, brain metastases, testicle cancer, hypophysis tumor, carcinoids, Kaposi's sarcoma, laryngeal cancer, germ cell tumor, bone cancer, colorectal carcinoma, head and neck tumors, colon carcinoma, craniopharyngiomas, oral cancer, cancer of the central nervous system, liver cancer, liver metastases, leukemia, eyelid tumor, lung cancer, lymph node cancer, lymphomas, stomach cancer, malignant melanoma, malignant neoplasia, malignant tumors of the gastrointestinal tract, breast carcinoma, rectal cancer, medulloblastomas, melanoma, meningiomas, Hodgkin's disease, mycosis fungoides, nasal cancer, neurinoma, neuroblastoma, kidney cancer, renal cell carcinomas, non-Hodgkin's lymphomas, oligodendroglioma, esophageal carcinoma,

osteolytic carcinomas and osteoplastic carcinomas, osteosarcomas, ovarian carcinoma, pancreatic carcinoma, penile cancer, plasmocytoma, prostate cancer, pharyngeal cancer, rectal carcinoma, retinoblastoma, vaginal cancer, thyroid carcinoma, Schneeberger disease, esophageal cancer, spinaliomas, T-cell lymphoma, thymoma, tube carcinoma, eye tumors, urethral cancer, urologic tumors, urothelial carcinoma, vulva cancer, wart appearance, soft tissue tumors, soft tissue sarcoma, Wilm's tumor, cervical carcinoma and tongue cancer.

14. The compound for use according to claim 9, wherein the TAM family receptor tyrosine kinase induced disorder is selected from the group comprising infectious diseases.

15. The compound for use according to any of claims 7-14, wherein said use is in combination with another anti-cancer agent, preferably an inhibitor of a growth factor receptor, more preferably an inhibitor of an epidermal growth factor receptor (EGFR) or of a vascular endothelial growth factor receptor (VEGFR), e. g. erlotinib, afatinib, cetuximab, panitumumab, lenvatinib, motesanib, regorafenib, and pazopanib.

16. A pharmaceutical composition comprising at least one compound according to any of claims 1-6, together with at least one pharmaceutically acceptable carrier, excipient and/or diluent.

17. The pharmaceutical composition according to claim 16, further comprising another anti-cancer agent, preferably an inhibitor of a growth factor receptor, more preferably an inhibitor of an epidermal growth factor receptor (EGFR) or of a vascular endothelial growth factor receptor (VEGFR), e. g. erlotinib, afatinib, cetuximab, panitumumab, lenvatinib, motesanib, regorafenib, and pazopanib.

18. Use of the compound of any of claims 1-6 in the manufacture of a medicament for the treatment of a disorder induced by TAM family receptor tyrosine kinase and/or Met receptor

tyrosine kinase, preferably a hyperfunction of said TAM family receptor tyrosine kinase and/or of said Met receptor tyrosine kinase, wherein the TAM family receptor tyrosine kinase induced disorder is selected from hyperproliferative disorders and infectious diseases.

19. Use according to claim 18, wherein the hyperproliferative disorders are selected from the group comprising cancer, in particular immune-suppressive cancer and primary tumor metastases.

20. Use according to claim 18, wherein the hyperproliferative disorders are selected refractory cancers.

21. Use according to claim 18, wherein the hyperproliferative disorders are selected from adenocarcinoma, choroidal melanoma, acute leukemia, acoustic neurinoma, ampullary carcinoma, anal carcinoma, astrocytoma, basal cell carcinoma, pancreatic cancer, desmoid tumor, bladder cancer, bronchial carcinoma, breast cancer, Burkitt's lymphoma, corpus cancer, CUP-syndrome, colorectal cancer, small intestine cancer, small intestinal tumors, ovarian cancer, endometrial carcinoma, ependymoma, epithelial cancer types, Ewing's tumors, gastrointestinal tumors, gastric cancer, gallbladder cancer, gall bladder carcinomas, uterine cancer, cervical cancer, cervix, glioblastomas, gynecologic tumors, ear tumors, nose tumors and throat tumors, hematologic neoplasias, hairy cell leukemia, urethral cancer, skin cancer, skin testis cancer, brain tumors, brain metastases, testicle cancer, hypophysis tumor, carcinoids, Kaposi's sarcoma, laryngeal cancer, germ cell tumor, bone cancer, colorectal carcinoma, head and neck tumors, colon carcinoma, craniopharyngiomas, oral cancer, cancer of the central nervous system, liver cancer, liver metastases, leukemia, eyelid tumor, lung cancer, lymph node cancer, lymphomas, stomach cancer, malignant melanoma, malignant neoplasia, malignant tumors of the gastrointestinal tract, breast carcinoma, rectal cancer, medulloblastomas, melanoma, meningiomas, Hodgkin's disease, mycosis fungoides, nasal cancer, neurinoma, neuroblastoma, kidney cancer, renal cell carcinomas, non-Hodgkin's lymphomas, oligodendroglioma, esophageal carcinoma, osteolytic carcinomas and osteoplastic carcinomas, osteosarcomas, ovarial carcinoma, pancreatic carcinoma, penile

cancer, plasmocytoma, prostate cancer, pharyngeal cancer, rectal carcinoma, retinoblastoma, vaginal cancer, thyroid carcinoma, Schneeberger disease, esophageal cancer, spinalioma, T-cell lymphoma, thymoma, tube carcinoma, eye tumors, urethral cancer, urologic tumors, urothelial carcinoma, vulva cancer, wart appearance, soft tissue tumors, soft tissue sarcoma, Wilm's tumor, cervical carcinoma and tongue cancer.

22. Use according to any of claims 18-21, wherein said use is in combination with another anti-cancer agent, preferably an inhibitor of a growth factor receptor, more preferably an inhibitor of an epidermal growth factor receptor (EGFR) or of a vascular endothelial growth factor receptor (VEGFR), e. g. erlotinib, afatinib, cetuximab, panitumumab, lenvatinib, motesanib, regorafenib, and pazopanib.